• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Envoy Medical Inc.

    6/12/26 4:30:46 PM ET
    $COCH
    Industrial Specialties
    Health Care
    Get the next $COCH alert in real time by email
    S-8 1 ea0293366-s8_envoy.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on June 12, 2026

    Registration No. 333-           

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

     

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

     

     

    ENVOY MEDICAL, INC.
    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   86-1369123
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (I.R.S. Employer
    Identification No.)

     

    4875 White Bear Parkway
    White Bear Lake, Minnesota
      55110
    (Address of Principal Executive Offices)   (Zip Code)

     

    Envoy Medical, Inc. Amended and Restated 2023 Equity Incentive Plan
    Envoy Medical, Inc. 2023 Employee Stock Purchase Plan
    (Full Title of the Plan)

     

    Brent T. Lucas
    Chief Executive Officer
    Envoy Medical, Inc.
    4875 White Bear Parkway
    White Bear Lake, Minnesota 55110
    (Name and Address of Agent for Service)

     

    (877) 900-3277
    (Telephone Number, including area code, of agent for service)

     

     

     

    Copies to:
    Andrew M. Nick
    Fredrikson & Byron, P.A.
    60 South Sixth Street; Suite 1500
    Minneapolis, MN 55402
    (612) 492-7000

     

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    PART I
    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.

     

    Information required by this Item 1 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”) and the instructions to Form S-8. In accordance with the rules and regulations of the Securities and Exchange Commission (the “Commission”) and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

     

    Item 2. Registrant Information and Employee Plan Annual Information.

     

    Information required by this Item 2 to be contained in the Section 10(a) prospectus is omitted from this Registration Statement in accordance with Rule 428 under the Securities Act and the instructions to Form S-8. In accordance with the rules and regulations of the Commission and the instructions to Form S-8, such documents are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 under the Securities Act.

     

    1

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents, which have been filed by Envoy Medical, Inc. (the “Registrant”) with the Commission, are incorporated by reference into this Registration Statement:

     

    (i)the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Commission on March 23, 2026;

     

    (ii)the Registrant’s Current Reports on Form 8-K (other than information furnished rather than filed), filed with the Commission on March 31, 2026, April 21, 2026, May 11, 2026, and May 18, 2026; and

     

    (iii)the description of the Registrant’s Common Stock which is contained in a registration statement on Form 8-A filed on March 1, 2021 (File No. 001-40133) under the Exchange Act, as updated by Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Commission on April 1, 2024, as well as any additional amendments or reports filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part hereof from the date of the filing of such documents, except as to specific sections of such statements as set forth therein.

     

    Unless expressly incorporated into this Registration Statement, a report furnished on Form 8-K prior or subsequent to the date hereof shall not be incorporated by reference into this Registration Statement, except as to specific sections of such statements as set forth therein. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document, which also is deemed to be incorporated by reference herein, modifies or supersedes such statement.

     

    Item 4. Description of Securities.

     

    Not applicable.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Not applicable.

     

    II-1

     

    Item 6. Indemnification of Directors and Officers.

     

    The Registrant’s second amended and restated certificate of incorporation contains provisions that limit the liability of the Registrant’s directors for monetary damages to the fullest extent permitted by Delaware law. Consequently, the Registrant’s directors will not be personally liable to the Registrant or its stockholders for monetary damages for any breach of fiduciary duties as directors, except liability for the following:

     

    ●for any breach of their duty of loyalty to the Registrant or its stockholders;

     

    ●for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;

     

    ●unlawful payments of dividends or unlawful stock repurchases or redemptions as provided in Section 174 of the Delaware General Corporation Law; or

     

    ●for any transaction from which they derived an improper personal benefit.

     

    The Registrant’s amended and restated bylaws provide that the Registrant shall indemnify, to the fullest extent permitted by law, any person who is or was a party or is threatened to be made a party to any action, suit or proceeding, by reason of the fact that he or she is or was one of the Registrant’s directors or officers or is or was serving at the Registrant’s request as a director or officer of another corporation, partnership, joint venture, trust, non-profit entity or other enterprise. The Registrant’s amended and restated bylaws provide that the Registrant may indemnify the Registrant’s employees or agents. The Registrant’s amended and restated bylaws also provide that the Registrant must advance expenses incurred by or on behalf of a director or officer in advance of the final disposition of any action or proceeding, subject to limited exceptions.

     

    The Registrant maintains insurance policies under which, subject to the limitations of the policies, coverage is provided to its directors and officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or officer, including claims relating to public securities matters, and to the Registrant with respect to payments that may be made by the Registrant to these officers and directors pursuant to the Registrant’s indemnification obligations or otherwise as a matter of law.

     

    The Registrant entered into indemnification agreements with each of its directors and executive officers that are broader than the specific indemnification provisions contained in the Delaware General Corporation Law. These indemnification agreements require the Registrant, among other things, to indemnify the Registrant’s directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Registrant to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding.

     

    Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Registrant’s company pursuant to the foregoing provisions, the Registrant has been informed that, in the opinion of the Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

     

    II-2

     

    Item 7. Exemption from Registration Claimed.

     

    Not applicable.

     

    Item 8. Exhibits

     

            Incorporated by Reference  
    Exhibit
    Number
      Description   Schedule/
    Form
      File No.   Exhibit   Filing
    Date
     
    4.1   Second Amended and Restated Certificate of Incorporation of Envoy Medical, Inc. (f/k/a Anzu Special Acquisition Corp I).   8-K   001-40133   3.1   October 5, 2023  
                           
    4.2   Amended and Restated Bylaws of Envoy Medical, Inc.   8-K   001-40133   3.2   October 5, 2023  
                           
    4.3   Certificate of Designation of Series A Preferred Stock of Envoy Medical, Inc.   8-K   001-40133   3.3   October 5, 2023  
                           
    5.1*   Opinion of Fredrikson & Byron, P.A.                  
                           
    23.1*   Consent of Grant Thornton LLP, independent registered public accounting firm of Envoy Medical, Inc.                  
                           
    23.2*   Consent of Fredrikson & Byron, P.A. (filed as part of Exhibit 5.1).                  
                           
    24.1*   Power of Attorney (filed as part of signature page).                  
                           
    99.1   Envoy Medical, Inc. Amended and Restated Equity Incentive Plan 2023 Equity Incentive Plan.   8-K   001-40133   10.1   June 3, 2025  
                           
    99.2   Envoy Medical, Inc. 2023 Employee Stock Purchase Plan.   8-K   001-40133   10.23   October 5, 2023  
                           
    99.3   Amendment No. 1 to Envoy Medical, Inc. Amended and Restated Equity Incentive Plan 2023 Equity Incentive Plan.   8-K   001-40133   10.1   May 18, 2026  
                           
    99.4   Amendment No. 1 to Envoy Medical, Inc. 2023 Employee Stock Purchase Plan.   8-K   001-40133   10.2   May 18, 2026  
                           
    107*   Filing Fee Table.                  

     

    * Filed herewith.

     

    II-3

     

    Item 9. Undertakings.

     

    a.The undersigned Registrant hereby undertakes:

     

    (1)To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

     

    (i)To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii)To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

     

    (iii)To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by such paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

     

    (2)That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3)To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    b.The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    c.Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered hereby, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

    II-4

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of White Bear Lake, State of Minnesota, on June 12, 2026.

     

      Envoy Medical, Inc.
         
      By: /s/ Brent T. Lucas
      Name: Brent T. Lucas
      Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned officers and directors of Envoy Medical, Inc., a Delaware corporation, do hereby constitute and appoint Brent T. Lucas and Robert M. Potashnick, and each of them, the lawful attorneys-in-fact and agents with full power and authority to do any and all acts and things and to execute any and all instruments which said attorneys and agents, and any one of them, determine may be necessary or advisable or required to enable said corporation to comply with the Securities Act of 1933, as amended, and any rules or regulations or requirements of the Securities and Exchange Commission in connection with this Registration Statement. Without limiting the generality of the foregoing power and authority, the powers granted include the power and authority to sign the names of the undersigned officers and directors in the capacities indicated below to this Registration Statement, to any and all amendments, both pre-effective and post-effective, and supplements to this Registration Statement, and to any and all instruments or documents filed as part of or in conjunction with this Registration Statement or amendments or supplements thereof, and each of the undersigned hereby ratifies and confirms that all said attorneys and agents, or any one of them, shall do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Brent T. Lucas   Chief Executive Officer and Director   June 12, 2026
    Brent T. Lucas   (Principal Executive Officer)    
             
    /s/ Robert M. Potashnick   Chief Financial Officer   June 12, 2026
    Robert M. Potashnick   (Principal Financial and Accounting Officer)    
             
    /s/ Charles R. Brynelsen   Director   June 12, 2026
    Charles R. Brynelsen        
             
    /s/ Michael Crowe   Director   June 12, 2026
    Michael Crowe        
             
    /s/ Mona Patel   Director   June 12, 2026
    Mona Patel        
             
    /s/ Charles S. McKhann   Director   June 12, 2026
    Charles S. McKhann        
             
    /s/ Janis Smith-Gomez   Director   June 12, 2026
    Janise Smith-Gomez        
             
    /s/ Susan J. Kantor   Director   June 12, 2026
    Susan J. Kantor        

     

    II-5

     

    Get the next $COCH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COCH

    DatePrice TargetRatingAnalyst
    3/31/2026$2.50Buy
    H.C. Wainwright
    6/24/2024$8.50Buy
    Ascendiant Capital Markets
    More analyst ratings

    $COCH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Patel Mona Chetan bought $125,000 worth of shares (312,500 units at $0.40), increasing direct ownership by 1,562% to 332,500 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:51:51 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Interim CFO Potashnick Robert bought $85,000 worth of shares (212,500 units at $0.40) (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:49:33 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Director Kantor Susan bought $38,460 worth of shares (96,150 units at $0.40), increasing direct ownership by 123% to 174,037 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    2/17/26 4:47:12 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    SEC Filings

    View All

    SEC Form EFFECT filed by Envoy Medical Inc.

    EFFECT - Envoy Medical, Inc. (0001840877) (Filer)

    6/17/26 12:15:15 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form POS AM filed by Envoy Medical Inc.

    POS AM - Envoy Medical, Inc. (0001840877) (Filer)

    6/12/26 4:31:10 PM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form S-8 filed by Envoy Medical Inc.

    S-8 - Envoy Medical, Inc. (0001840877) (Filer)

    6/12/26 4:30:46 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $COCH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th

    NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Sciences Virtual Investor Forum, taking place June 24th & 25th, 2026. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE Investors are encouraged to pre-register and run the online system check to expedite participation and receive event updates. Participation is free, and attendees may watch live company presentations and schedule one-on-one meetings with management teams. Schedule 1x1 meetings here. "This week's Life Sciences Virtual Investor Forum brings

    6/23/26 8:35:00 AM ET
    $MTVA
    $NSRX
    $CTSO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Industrial Specialties

    Envoy Medical to Present at Investor Conferences on June 25th

    White Bear Lake, Minnesota--(Newsfile Corp. - June 18, 2026) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Virtual Life Sciences Investor Forum and the Biotech Webull Webinar Panel on June 25, 2026.Life Sciences Virtual Investor ForumDates: June 24th & 25thPresentation Day and Time: Thursday, June 25, 2026, at 1:00 p.m. ETWebcast Link Biotech Webull Webinar PanelPresentation Day and Time: Thursday, June 25, 2026, at 2:40 p.m. ETWebcast LinkTo schedule a meeting with the Envoy Medicals management team, please contact KCSA

    6/18/26 8:30:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical to Present at Planet MicroCap Conference Las Vegas on June 16th-18th

    White Bear Lake, Minnesota--(Newsfile Corp. - June 4, 2026) - Envoy Medical® Inc. (NASDAQ:COCH), a hearing health company pioneering fully implanted hearing solutions, today announced that Brent Lucas, CEO of Envoy Medical, will present at the Planet MicroCap Conference on June 16-18, 2026, in Las Vegas, NV.Planet MicroCap Las Vegas 2026Dates: June 16-18, 2026Location: Bellagio Hotel & Casino, Las Vegas, NVBooth: #410Presentation Day and Time: Wednesday, June 17, 2026, at 11:00 A.M. PTPresentation Location: Track 7 - Donatello 3Webcast: Viewable hereThe Company will be participating in one-on-one investor meetings throughout the event. For more information about the conference, or to schedul

    6/4/26 8:30:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    H.C. Wainwright initiated coverage on Envoy Medical with a new price target

    H.C. Wainwright initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $2.50

    3/31/26 8:12:03 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Ascendiant Capital Markets initiated coverage on Envoy Medical with a new price target

    Ascendiant Capital Markets initiated coverage of Envoy Medical with a rating of Buy and set a new price target of $8.50

    6/24/24 7:29:10 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Lucas Brent T.

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/23/26 6:28:40 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Chief Executive Officer Lucas Brent T. was granted 32,856 shares, increasing direct ownership by 11% to 329,946 units (SEC Form 4)

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    6/4/26 4:28:22 PM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Mckhann Chas

    4 - Envoy Medical, Inc. (0001840877) (Issuer)

    4/17/26 4:32:04 PM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Leadership Updates

    Live Leadership Updates

    View All

    Envoy Medical Appoints Chas McKhann to Board of Directors

    Proven Med Tech Leader with an Established Track Record of Commercial Success and Optimizing Shareholder Value Leading to over $3.4 Billion in Successful ExitsWhite Bear Lake, Minnesota--(Newsfile Corp. - April 16, 2026) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a hearing health company pioneering fully implanted hearing solutions, today announced the appointment of Chas McKhann, a seasoned medical technology executive with documented success, to its Board of Directors.Mr. McKhann is a well-known and respected med tech leader with extensive experience creating and executing commercialization plans that have scaled into high-growth companies creating significant shareholder valu

    4/16/26 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board

    Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversionWhite Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ:COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A. Taylor, who also announced his retirement from the Envoy Medical board after two decades of ser

    8/26/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Announces Addition of Medical Device Manufacturing Experience to its Board of Directors to Prepare for Scaling

    WHITE BEAR LAKE, Minn., June 11, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. ("Envoy Medical") (NASDAQ:COCH) today announced the appointment of Michael Crowe to the Envoy Medical Board of Directors effective June 7, 2024. Envoy Medical is currently sponsoring an Early Feasibility Study at Mayo Clinic in Rochester, Minnesota for its investigational fully implanted Acclaim® Cochlear Implant. Envoy Medical expects to begin a larger pivotal clinical study for its device later in 2024. Mr. Crowe, who received his BS in Electrical Engineering from the University of Louisville and his MBA from Duke University, has decades of experience helping companies grow operations quickly and efficiently

    6/11/24 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    $COCH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    $COCH
    Financials

    Live finance-specific insights

    View All

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/14/24 8:49:34 AM ET
    $COCH
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Envoy Medical Inc.

    SC 13G - Envoy Medical, Inc. (0001840877) (Subject)

    11/13/24 4:40:10 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports on Second Quarter 2025 Results

    White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events.Financial and Corporate Highlights for Second Quarter and to date:Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.Successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. A

    7/31/25 8:00:00 AM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports on First Quarter 2025 Results

    Company Provides Update on Its Pivotal Clinical Study for Fully Implanted Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - May 1, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the first quarter ended March 31, 2025, as well as other subsequent events.Financial and Corporate Highlights for First Quarter and to date:Secured additional $10 Million in funding to advance Pivotal Clinical Trial. Completed Enrollment of 10 participants in "first stage" of Pivotal Clinical Trial of the fully implanted Acclaim® cochlear implant.Activat

    5/1/25 4:30:00 PM ET
    $COCH
    Industrial Specialties
    Health Care

    Envoy Medical Reports Fourth Quarter and Full Year 2024 Financial Results

    Company Provides Corporate Update that Includes Information on its Progress Enrolling Subjects in its Pivotal Clinical Study for Breakthrough Device, the Fully Implanted Acclaim® Cochlear ImplantWhite Bear Lake, Minnesota--(Newsfile Corp. - March 31, 2025) - Envoy Medical®, Inc. (NASDAQ:COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the fourth quarter and full year ended December 31, 2024, as well as other subsequent events.Brent Lucas, CEO of Envoy Medical commented: "Envoy Medical had a successful 2024 and we are off to a wonderful start in 2025. Obtaining FDA's approval to

    3/31/25 9:15:00 AM ET
    $COCH
    Industrial Specialties
    Health Care